Latest Health It Market News

nib Holdings reported a solid FY25 with underlying operating profit of $239.2 million and 3.2% policyholder growth, driven by digital innovation and operational efficiencies. The Group’s strategic focus on core health insurance and adjacent services sets the stage for continued momentum into FY26.

The a2 Milk Company delivered record FY25 results with $1.9 billion in sales and announced a transformative acquisition of a New Zealand manufacturing facility, alongside divesting its stake in Mataura Valley Milk and planning a $300 million special dividend.

Savannah Goldfields reported a $4.06 million cash outflow in Q2 2025 but is advancing plans to restart gold production and secure additional funding.

McPherson’s Limited anticipates FY25 revenue around $139 million with a strong second-half EBITDA rebound, while its strategic shift to third-party wholesalers sets the stage for significant EBIT gains in FY26.

AMP Limited is set to defend itself against a new class action alleging inflated life insurance premiums and a separate dispute over a major property sale, signaling potential challenges ahead for the financial services giant.

Adherium Limited is raising up to $4 million through a partially underwritten entitlement offer to expand its US digital health platform and recruit key personnel. The capital raise supports scaling patient onboarding and advancing its FDA-cleared smart inhaler technology.

EZZ Life Science has launched its US-focused brand EZZDAY with four FDA-registered supplements, marking a major step in its international growth strategy. The company has also begun US-based manufacturing and opened an online store to target American consumers.

Monash IVF Group has affirmed its compliance with ASX continuous disclosure rules following a clinical incident involving an embryo transfer error at its Clayton laboratory. The company clarified the materiality and timing of its disclosures in response to ASX inquiries.

Proteomics International has validated its PromarkerEndo blood test as a highly accurate, non-invasive diagnostic tool for endometriosis, with commercial launch planned in Australia for Q3 2025. The test promises to reduce the average seven-year diagnostic delay by providing a simple risk score applicable across all disease stages.

Optiscan Imaging Ltd has revealed its next-generation InForm™ pathology imaging device and strengthened its executive team, while reporting a robust cash position supported by a $1.775 million R&D tax refund for the quarter ended 31 March 2025.

Biome Australia is set to expand its Activated Probiotics range with two new products targeting vaginal health and perinatal care, tapping into a booming women’s health supplements market.

Alcidion has secured its first contract in Wales with Hywel Dda University Health Board, deploying its Miya Precision Platform to enhance patient flow and clinical communication over five years.